Trials / Recruiting
RecruitingNCT07160725
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy in Adult Participants With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 315 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986517 | Specified dose on specified days |
Timeline
- Start date
- 2025-10-15
- Primary completion
- 2028-07-31
- Completion
- 2028-08-01
- First posted
- 2025-09-08
- Last updated
- 2026-03-24
Locations
19 sites across 4 countries: United States, Denmark, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07160725. Inclusion in this directory is not an endorsement.